The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access.
Terstappen J. et al, (2024), The Lancet. Infectious diseases, 24, e747 - e761
New SARS-CoV-2 Omicron Variant with Spike Protein Mutation Y451H, Kilifi, Kenya, March-May 2023.
Mwanga MJ. et al, (2023), Emerging infectious diseases, 29, 2376 - 2379
Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults
Green C. et al, (2023), Clinical and Experimental Immunology, 211, 269 - 279
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape.
Mazur NI. et al, (2023), The Lancet. Infectious diseases, 23, e2 - e21
Development of a controlled human infection model to study respiratory syncytial virus infection in older adults.
Sande CJ., (2022), The lancet. Healthy longevity, 3, e370 - e371
Identifying the research, advocacy, policy and implementation needs for the prevention and management of respiratory syncytial virus lower respiratory tract infection in low- and middle-income countries.
Carbonell-Estrany X. et al, (2022), Frontiers in pediatrics, 10
Implementation strategies for passive respiratory syncytial virus immunisation.
Sande CJ., (2021), The Lancet. Infectious diseases, 21, 1200 - 1201
Respiratory syncytial virus in young children: community cohort study integrating serological surveys, questionnaire and electronic health records, Born in Bradford cohort, England, 2008 to 2013.
Zylbersztejn A. et al, (2021), Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 26
Enrichment approach for unbiased sequencing of respiratory syncytial virus directly from clinical samples.
Waweru JW. et al, (2021), Wellcome open research, 6
Presumed Risk Factors and Biomarkers for Severe Respiratory Syncytial Virus Disease and Related Sequelae: Protocol for an Observational Multicenter, Case-Control Study From the Respiratory Syncytial Virus Consortium in Europe (RESCEU).
Jefferies K. et al, (2020), The Journal of infectious diseases, 222, S658 - S665
Priorities for developing respiratory syncytial virus vaccines in different target populations
Drysdale SB. et al, (2020), Science Translational Medicine, 12
Vaccination against Respiratory Syncytial Virus.
Green CA. et al, (2020), Interdisciplinary topics in gerontology and geriatrics, 43, 182 - 192
Author Correction: Airway response to respiratory syncytial virus has incidental antibacterial effects.
Sande CJ. et al, (2019), Nature communications, 10
Airway response to respiratory syncytial virus has incidental antibacterial effects.
Sande CJ. et al, (2019), Nature communications, 10
Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.
Green CA. et al, (2019), The Journal of infection, 78, 382 - 392
Agreement between ELISA and plaque reduction neutralisation assay in Detection of respiratory syncytial virus specific antibodies in a birth Cohort from Kilifi, coastal Kenya.
Nyiro JU. et al, (2019), Wellcome open research, 4
Respiratory syncytial virus: diagnosis, prevention and management.
Barr R. et al, (2019), Therapeutic advances in infectious disease, 6
Antibodies in lymphocyte supernatants can distinguish between neutralising antibodies induced by RSV vaccination and pre-existing antibodies induced by natural infection
Gerretsen HE. et al, (2018), Vaccine, 36, 6988 - 6994